UNAIR NEWS 51动漫 has focused developing potential researches for downstream operations by the industrials and institutes. As a proof, both UNAIR officials and Health Research and Development agency (Balitbangkes) of Ministry of Health have extended partnership on product mass production on Saturday, August 5.
The signing session of the MoU was done by Vice Rector IV UNAIR and Head of Balitbangkes Kemenkes Siswanto, dr., MHP., DTM. In the same occasion, Head of Research and Innovation Institute UNAIR Prof. Hery Purnobasuki, Ph.D also signed an MoU with Head of Herbal and Traditional Drug Balitbangkes, Dra. Lucie Widowati, M.Si., Apt.
According to Vice Rector IV UNAIR, the collaboration between UNAIR and Balitbangkes can accelerate the downstream product management process.
淯NAIR Research in Health can achieve downstream operation stage if the researchers forge partnership with the industrials and regulators. The goal is to get approval and meet the requirement from Balitbangkes and BPOM (Drug and Food Monitoring Agency), he said after the meeting in Plenary room, Management Office Building.
Junaidi explained that the product to go into downstream operation is antimalarial drugs from Siamese Cassia (Cassia siamea lam). The antimalarial drugs developed by a lecturer in Faculty of Pharmacy UNAIR Dr. Wiwied Ekasari, M.Si., Apt., is already in clinical trial phase 1. It means that the research on active compound genetic profil of Siamese Cassia is being conducted.
Balitbangkes will give some research developmental fund to support the research. It will be used for the research, publication process in reputable international journals until the development of the products.
Head of Balitbangkes said that the antimalarial drug can be an alternative for the drug generally used. Therefore, Balitbangkes and the industrials need to monitor the development of this antimalarial drugs.
淲e expected research guidance in the country which later to be mass produced, said Siswanto.
The same collaboration has been done by UNAIR and Balitbangkes. In the previous research, they worked on antidengue drug, AviMac, research. It was extended for the next five years.
Author: Defrina Sukma S
